Mechanism of action

Kisspeptin signaling operates upstream of gonadotropin-releasing hormone (GnRH), the signal that drives pituitary gonadotropin secretion. KISS1R is the receptor historically called GPR54. Kotani and colleagues identified kisspeptin-family ligands and characterized receptor activation in cell models, including calcium mobilization and intracellular signaling. George and colleagues subsequently examined kisspeptin-10 in healthy men: serum luteinizing hormone (LH) rose after exposure, and infusion experiments altered LH pulse frequency and size. These circulating hormone measurements support activation of the reproductive axis but are an indirect measure of GnRH activity. The effect also depends on the hormonal setting. Research in women indicates that menstrual phase and prevailing sex-steroid feedback modify the response, so a finding in one group cannot be assumed to apply across populations.

State of evidence

The evidence includes early human experiments on kisspeptin-10 itself. George et al. (2011) compared responses with vehicle in healthy men, using small groups to examine acute LH responses and pulsatility. Jayasena et al. (2011) studied men and women and found a different response pattern across menstrual phases: women in the follicular phase did not show the gonadotropin response seen in men or in the preovulatory setting. George et al. (2012) further investigated sex-steroid feedback in women and reported differences between postmenopausal, early-follicular and contraceptive-using groups. These are physiological studies with limited participant numbers and hormone endpoints. They do not demonstrate improved fertility, durable endocrine correction or long-term safety. As checked on 30 September 2026, the phase 1 registry study NCT07224490 is recruiting and has no posted results. Results for the longer kisspeptin-54 fragment or other receptor agonists require their own assessment; the shared receptor does not make their clinical evidence interchangeable.

Questions about the research

Is kisspeptin-10 the same substance as kisspeptin-54?

No. The numbers describe different peptide lengths. They belong to the same family and share a biologically important terminal region, but they are distinct molecules. An article on kisspeptin-10 must identify which fragment each experiment used. A result from kisspeptin-54, including a fertility or behavioral endpoint, is not direct evidence for kisspeptin-10.

What did the human kisspeptin-10 experiments measure?

They measured circulating reproductive hormones and, in some experiments, analyzed LH pulse patterns. The response varied with participant characteristics and sex-steroid context. Those measurements help investigate the signaling pathway. They are not equivalent to demonstrating a clinical benefit, restoring fertility or correcting a hormone disorder.

Does this evidence establish the properties of a research product?

No. The publications describe material used under controlled experimental conditions. Substance identity, purity and handling affect how an experiment can be interpreted, and a product label alone cannot establish equivalence to study material. Human safety, effective treatment and long-term outcomes cannot be inferred from these early physiological findings.

Sources

1. Kotani et al., J Biol Chem 2001DOI: 10.1074/jbc.M104847200PMID: 11457843
2. George et al., J Clin Endocrinol Metab 2011DOI: 10.1210/jc.2011-0089PMID: 21632807
3. Jayasena et al., J Clin Endocrinol Metab 2011DOI: 10.1210/jc.2011-1408PMID: 21976724
4. George et al., Hum Reprod 2012DOI: 10.1093/humrep/des326PMID: 22956346
5. ClinicalTrials.gov, NCT07224490 (record checked 2026-09-30)

Mechanism of action

Kisspeptin signaling operates upstream of gonadotropin-releasing hormone (GnRH), the signal that drives pituitary gonadotropin secretion. KISS1R is the receptor historically called GPR54. Kotani and colleagues identified kisspeptin-family ligands and characterized receptor activation in cell models, including calcium mobilization and intracellular signaling. George and colleagues subsequently examined kisspeptin-10 in healthy men: serum luteinizing hormone (LH) rose after exposure, and infusion experiments altered LH pulse frequency and size. These circulating hormone measurements support activation of the reproductive axis but are an indirect measure of GnRH activity. The effect also depends on the hormonal setting. Research in women indicates that menstrual phase and prevailing sex-steroid feedback modify the response, so a finding in one group cannot be assumed to apply across populations.

State of evidence

The evidence includes early human experiments on kisspeptin-10 itself. George et al. (2011) compared responses with vehicle in healthy men, using small groups to examine acute LH responses and pulsatility. Jayasena et al. (2011) studied men and women and found a different response pattern across menstrual phases: women in the follicular phase did not show the gonadotropin response seen in men or in the preovulatory setting. George et al. (2012) further investigated sex-steroid feedback in women and reported differences between postmenopausal, early-follicular and contraceptive-using groups. These are physiological studies with limited participant numbers and hormone endpoints. They do not demonstrate improved fertility, durable endocrine correction or long-term safety. As checked on 30 September 2026, the phase 1 registry study NCT07224490 is recruiting and has no posted results. Results for the longer kisspeptin-54 fragment or other receptor agonists require their own assessment; the shared receptor does not make their clinical evidence interchangeable.

Questions about the research

Is kisspeptin-10 the same substance as kisspeptin-54?

No. The numbers describe different peptide lengths. They belong to the same family and share a biologically important terminal region, but they are distinct molecules. An article on kisspeptin-10 must identify which fragment each experiment used. A result from kisspeptin-54, including a fertility or behavioral endpoint, is not direct evidence for kisspeptin-10.

What did the human kisspeptin-10 experiments measure?

They measured circulating reproductive hormones and, in some experiments, analyzed LH pulse patterns. The response varied with participant characteristics and sex-steroid context. Those measurements help investigate the signaling pathway. They are not equivalent to demonstrating a clinical benefit, restoring fertility or correcting a hormone disorder.

Does this evidence establish the properties of a research product?

No. The publications describe material used under controlled experimental conditions. Substance identity, purity and handling affect how an experiment can be interpreted, and a product label alone cannot establish equivalence to study material. Human safety, effective treatment and long-term outcomes cannot be inferred from these early physiological findings.

Sources

1. Kotani et al., J Biol Chem 2001DOI: 10.1074/jbc.M104847200PMID: 11457843
2. George et al., J Clin Endocrinol Metab 2011DOI: 10.1210/jc.2011-0089PMID: 21632807
3. Jayasena et al., J Clin Endocrinol Metab 2011DOI: 10.1210/jc.2011-1408PMID: 21976724
4. George et al., Hum Reprod 2012DOI: 10.1093/humrep/des326PMID: 22956346
5. ClinicalTrials.gov, NCT07224490 (record checked 2026-09-30)